Home fetal monitoring shows promise but needs stronger evidence, systematic review finds

Researchers have spent decades trying to figure out whether pregnant women can safely monitor their babies' heart rates at home instead of making repeated trips to the hospital. A new systematic review of 39 studies involving 7,240 participants across 13 countries suggests the answer is cautiously yes—but the evidence is shakier than we'd like it to be.

The review, published in PLOS Digital Health, examined home cardiotocography (CTG) monitoring, a technology that lets pregnant women use a handheld device to record fetal heart tracings and transmit them to clinicians for review. The motivation is straightforward: as more pregnancies are classified as high-risk, maternity clinics are overwhelmed. Women with conditions like gestational diabetes, hypertension, or preterm rupture of membranes may need monitoring multiple times a week. Home monitoring could ease that burden.

When researchers pooled data from seven randomized controlled trials comparing home CTG to standard hospital care, they found no significant differences in the outcomes that matter most. Emergency caesarean sections occurred at similar rates in both groups. Perinatal mortality showed no meaningful difference. Rates of preterm birth, low Apgar scores, and neonatal admission were comparable. Women assigned to home monitoring reported similar levels of depression and anxiety as those receiving conventional care. On paper, home monitoring looked as safe as the established approach.

But here's the catch: the researchers graded the certainty of this evidence as low or very low using a standard scientific framework called GRADE. Why? The included trials were small—many enrolled fewer than 100 participants. Study designs varied widely, making it hard to compare results. Several trials had methodological flaws that introduced bias. And some studies were decades old, using outdated technology like telephone transmission instead of internet-based systems. When you combine these weaknesses, you get findings that look reassuring but rest on shaky ground.

The feasibility data painted a more encouraging picture. When researchers examined 23 observational studies focused on whether the technology actually worked in practice, they found that remote CTG tracings were interpretable 74 to 100 percent of the time—most studies reported success rates above 90 percent. Transmission failures were rare, typically 1 to 16 percent, and usually caused by equipment problems or poor internet connectivity rather than device failure. Women reported high satisfaction with the devices, citing convenience, reduced travel time, and the ability to stay home with their families. Clinicians appreciated the potential to reduce clinic crowding, though some expressed anxiety about losing direct control over patient care.

The economic analysis revealed an unexpected benefit. Although setting up a home CTG service cost between £1,524 and £52,000 initially, studies consistently showed savings of £1,552 to £2,113 per participant during pregnancy. These savings came from fewer hospital admissions, reduced clinic visits, and lower travel costs. When researchers factored in all expenses—equipment, staff time, clinic visits, and inpatient stays—home monitoring cost £223.83 less per woman than conventional care for antenatal management. The initial investment could be recovered relatively quickly if the service was offered to enough women over time.

Yet significant gaps remain. Only 28 percent of studies clearly described what would trigger a woman to go to the hospital if her home CTG looked abnormal. Safety protocols were vague or missing in most research. No study adequately assessed the impact of home monitoring on emergency department visits—a crucial metric for understanding whether the technology actually reduces pressure on maternity services or simply shifts it elsewhere. Training requirements for women to use the devices properly were rarely documented. And critically, all 39 included studies came from high-income countries. There was not a single study from a low- or middle-income country, despite the fact that perinatal mortality is far higher in those regions and the need for remote monitoring may be most urgent there.

The researchers identified a troubling pattern in who participated in home monitoring trials. Women with lower education levels were underrepresented, suggesting that digital literacy—the ability to use technology confidently—may be a barrier. If home CTG monitoring is implemented widely, it risks widening health disparities by serving educated, affluent women while leaving others behind. The review also noted that future research must establish which high-risk patient groups would benefit most from home monitoring versus those who need in-person hospital care. Predictive tools that identify women at highest risk of complications could help clinicians make that decision. Finally, the environmental cost of manufacturing devices, transmitting data, and managing electronic waste deserves consideration as these technologies scale up.